Department of Neurology, Odense University Hospital, Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Sdr. Boulevard 29, 5000 Odense C, Denmark.
Eur J Cancer. 2013 Oct;49(15):3303-10. doi: 10.1016/j.ejca.2013.05.026. Epub 2013 Jun 22.
We investigated the influence of hormone replacement therapy (HRT) use on the risk of meningioma in a population-based setting.
We conducted a nationwide case-control study in Denmark based on population-based administrative and health registries. The study included all female patients aged 55-84 years with a first time diagnosis of meningioma during 2000-2009. The cases were matched on birth year with female population controls. Ever use of HRT since 1995 was defined as ≥2 HRT prescriptions and categorised according to HRT type (oestrogen only, combined oestrogen-progestagen, and progestagen only) and cumulated duration of use (<1, ≥1 to <5, ≥5 to <10, ≥10 years). We used conditional logistic regression to compute odds ratios (ORs), with 95% confidence intervals (CIs), for meningioma associated with HRT use, and adjusting for potential confounders.
We identified 924 cases and 6122 controls. Ever use of HRT was associated with an increased risk of meningioma (OR, 1.3; 95%CI, 1.1-1.5) compared with non-use (0-1 prescriptions). The risk increased with increasing duration of HRT use, reaching an OR of 1.7 (95% CI, 1.2-2.3) after more than 10 years of use. The risk of meningioma associated with long-term (≥10 years) HRT use was most pronounced for combined oestrogen-progestagen therapy (OR, 2.2; 95% CI, 1.4-3.3), especially when this regimen constituted the sole HRT therapy (OR, 2.7; 95% CI, 0.9-7.5), although the latter estimate was based on small numbers.
Long-term HRT use, particularly of combined oestrogen-progestagen therapy, may increase the risk of meningioma.
我们旨在人群中研究激素替代疗法（HRT）的使用对脑膜瘤风险的影响。
我们在丹麦进行了一项基于人群的病例对照研究，该研究基于基于人群的行政和健康登记处。该研究包括所有 55-84 岁女性患者，这些患者在 2000-2009 年间首次诊断为脑膜瘤。这些病例按出生年份与女性人群对照相匹配。自 1995 年以来，曾经使用 HRT 被定义为至少 2 次 HRT 处方，并根据 HRT 类型（仅雌激素、联合雌激素-孕激素和孕激素）和累积使用时间（<1、≥1-<5、≥5-<10、≥10 年）进行分类。我们使用条件逻辑回归计算与 HRT 使用相关的脑膜瘤的比值比（OR），置信区间（CI）为 95%，并调整了潜在的混杂因素。
我们确定了 924 例病例和 6122 例对照。与未使用 HRT（0-1 个处方）相比，曾经使用 HRT 与脑膜瘤的风险增加相关（OR，1.3；95%CI，1.1-1.5）。随着 HRT 使用时间的增加，风险也随之增加，在使用超过 10 年之后，OR 达到 1.7（95%CI，1.2-2.3）。与长期（≥10 年）HRT 使用相关的脑膜瘤风险，对于联合雌激素-孕激素治疗最为显著（OR，2.2；95%CI，1.4-3.3），尤其是当这种方案构成唯一的 HRT 治疗时（OR，2.7；95%CI，0.9-7.5），尽管后一个估计值基于较小的样本量。
长期使用 HRT，特别是联合雌激素-孕激素治疗，可能会增加脑膜瘤的风险。
